

References:

1. *Gidwani UK, Mohanty B, Chatterjee K*: The pulmonary artery catheter: a critical reappraisal. *Cardiol Clin* 2013; 31: 545–65, viii. doi: 10.1016/j.ccl.2013.07.008.
2. *Aggarwal N, Kupfer Y, Yoon TS, Tessler S*: Pulmonary artery catheter coiled in the main pulmonary artery trunk. *BMJ Case Rep* 2013; 2013. doi: 10.1136/bcr-2013-200049.
3. *Starzyk L, Yao E, Roche-Nagel G, Wasowicz M*: Snaring swans: intraoperative knotting of pulmonary artery catheters. *Anaesthesiol Intensive Ther* 2016; 48: 66–70. doi: 10.5603/AIT.2016.0013.
4. *Swan HJ, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D*: Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. *N Engl J Med* 1970; 283: 447–451.
5. *Palmieri TL*: The inventors of the Swan-Ganz catheter: H.J.C. Swan and William Ganz. *Curr Surg* 2003; 60: 351–352.
6. *Binanay C, Califf RM, Hasselblad V et al.*: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *JAMA* 2005; 294: 1625–1633.
7. *Harvey S, Harrison DA, Singer M et al.*: Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. *Lancet* 2005; 366: 472–477.
8. *Narumiya C, Isobe F*: Insertion procedure of the Swan-Ganz catheter. *Kyobu Geka* 2010; 63 (8 Suppl): 607–611.
9. *Fleisher AG, Tyers GF, Manning GT, Nelems B*: Management of massive hemoptysis secondary to catheter-induced perforation of the pulmonary artery during cardiopulmonary bypass. *Chest* 1989; 95: 1340–1341.
10. *Kearney TJ, Shabot MM*: Pulmonary artery rupture associated with the Swan-Ganz catheter. *Chest* 1995; 108: 1349–1352.
11. *Chemchik H, Hassen MB, Turki M et al.*: Intracardiac node of Swan-Ganz catheter: report of a case. *Pan Afr Med J* 2013; 14: 137. doi: 10.11604/pamj.2013.14.137.
12. *Lopes MC, de Cleve R, Zilberstein B, Gama-Rodrigues JJ*: Pulmonary artery catheter complications: report on a case of a knot accident and literature review. *Rev Hosp Clin Fac Med Sao Paulo* 2004; 59: 77–85.

Corresponding author:

Bin Wang
Union Hospital, Tongji Medical College
of Huazhong University of Science and Technology
Wuhan, Hubei
e-mail: yxsxs2015@sohu.com

Anesthesiology Intensive Therapy
 2016, vol. 48, no 5, 370–372
 ISSN 0209–1712
 10.5603/AIT.2016.0049
 www.ait.viamedica.pl

Isolated lower limb gangrene: a caveat of terlipressin therapy

Ankur Khandelwal, Devendra Gupta,
 Rudrashish Haldar, Anindita Rai

Department of Anaesthesiology, Sanjay Gandhi Post Graduate Institute Of Medical Sciences (Sgpgims), Lucknow, Uttar Pradesh, India

Sir,

Terlipressin is a synthetic analogue of the natural hormone arginine–vasopressin. It is often employed for the management of bleeding esophageal varices (BEV) and hepatorenal syndrome (HRS), both of which are catastrophic complications of advanced liver disease. Being a vasoconstrictor with preferential action on the splanchnic circulation, it aids the lowering of portal venous pressure. Terlipressin usage during BEV has been shown to decrease mortality, the failure rate of initial hemostasis, as well as the number of emergency procedures to stop uncontrolled bleeding or rebleeding [1]. In spite of its relatively safer pharmacological profile as compared to vasopressin, complications attributed to systemic vasoconstrictor properties have been occasionally reported. We encountered a case of isolated lower-limb gangrene following terlipressin therapy and wish to report it after obtaining informed written consent from the relatives.

A 67-year-old male patient with a history of alcohol-related chronic liver disease (CLD) and portal hypertension (7 years duration) was admitted to our ICU following one episode of haemetemesis, deteriorating sensorium and reduced urine output (approx. 300 mL day⁻¹) during the

previous 48 hours. The patient was an active smoker with a history of 45 pack-years. His daily intake of alcohol had been 150 g for 38 years. He had discontinued alcohol consumption 7 years ago following the initial identification of alcohol-related cirrhosis. On admission, the patient was afebrile, haemodynamically stable and icteric. After initial examination and investigations, patient was diagnosed provisionally as acute-on-chronic liver disease with decompensation and HRS. Since the concern of aspiration existed due to an ongoing oesophageal bleed and depressed sensorium secondary to hepatic encephalopathy, the patient was intubated and put on mechanical ventilation using the Continuous Positive Airway Pressure (CPAP) mode.

Subsequently, endoscopic variceal band ligation (EVL) was attempted but the procedure failed due to a persistent haemorrhage. Therefore, terlipressin therapy was considered. The patient was administered an initial bolus of terlipressin (2 mg stat) followed by 1 mg every 4 hours. Concomitantly, a 20% albumin solution infusion was commenced at a dose of 1 g kg⁻¹ day⁻¹ for the 1st day followed by 20 g day⁻¹ in view of HRS. Packed Red Blood Cells (PRBCs) and blood products were transfused based on existing haemoglobin levels, the coagulation profile and thromboelastography. After the initial conservative measures had stabilised the patient, EVL was again attempted on the 3rd day and was carried out successfully.

On the 4th day, however, a new onset of blackish discoloration of the skin of all the toes of the left foot, along with the distal part of the foot on both the dorsal and ventral aspects, were noticed. Similar changes, but of a lesser



Figure 1. Blackish discolouration of skin of all the toes of the left foot, along with distal part of the same foot. Similar changes, but of lesser magnitude, may also be noticed on the great toe and 2nd toe of the right foot

magnitude were also noticed on the great toe and the 2nd toe of the right foot (Fig. 1). An urgent Doppler ultrasound was performed which demonstrated normal blood flow in the major arteries (superficial femoral, popliteal, anterior tibial, posterior tibial, peroneal and dorsalis pedis) of both lower limbs, while also confirming the patency of the venous channels. Such changes were, however, absent on other body parts. Terlipressin injections were stopped immediately and oral sildenafil (50 mg twice a day) was started on the same day. However, the gangrenous changes did not resolve until the 14th day when the patient expired due to systemic complications of ongoing severe sepsis and acute respiratory distress syndrome (ARDS).

Since its introduction in the early 1990s, terlipressin has emerged as a frontline therapy in order to manage BEV and HRS. Its advantages include its potency, prolonged half-life (6 hours), relative safety and easy administration in intravenous boluses. While terlipressin acts selectively on the splanchnic circulation, it can exert vasoconstrictor effects on the systemic circulation. Therefore, systemic sequelae ranging from mild ischaemic complications to serious complications like ischaemic colitis, myocardial infarction and skin necrosis can be attributed to terlipressin usage. The frequency of ischaemic complications after terlipressin therapy for HRS is reported to be 5% [2]. Le Moine *et al.* [3] reported the absence of ischaemic complications following high doses of terlipressin (1 mg every 4 hours) administration to a patient with HRS over 2 months. Conversely, gangrenous changes on the toes have been reported to appear on the very first day of terlipressin therapy [4]. Ischaemic events, therefore, are probably independent of the duration of terlipressin therapy. This necessitates the recognition of certain risk factors like hypovolemia, the concomitant administration of pressor drugs and the mode of terlipressin administration [5]. Generally, continuous intravenous infusion of terlipressin is not rec-

ommended as the mode of administration, since it causes cutaneous (at the infusion site) and scrotal necrosis [6]. The ischaemic complications secondary to terlipressin therapy are probably related to the particular distribution of the target receptor of terlipressin — the vasopressin receptor type 1 (V_1 receptor) — which is located in the smooth muscles of the blood vessels, mainly in the territory of the splanchnic circulation, kidney, myometrium, bladder, adipocytes and skin circulation [7]. However, preferential involvement of a particular site has not yet been fully explained.

In our case, terlipressin was administered as an intravenous bolus while the risk factors involved were chronic alcoholism and smoking. The peripheral vasoconstrictive changes secondary to prolonged smoking may have exaggerated and accelerated the development of limb gangrene.

Terlipressin should be stopped immediately once the ischaemic events are suspected. Ischaemic changes in both the lower limbs have been reported to have regressed and recovered in 2 weeks after the discontinuation of terlipressin [8]. In contrast, Coskun *et al.* [1] reported that skin necrosis on the forearm progressed for 1 week even after terlipressin discontinuation. Thus, cessation of terlipressin does not always necessarily result in the regression of gangrenous changes.

Various vasodilators have been tried as rescue therapy with variable success rates. These include alprostadil (PGE1 analogue) [9], sildenafil [10] and nitrates [11] as reported by various authors. Nevertheless, amputation remains the last resort in limb gangrene. In our patient, terlipressin-induced ischemia led to necrosis and gangrene of both feet. Despite the timely cessation of terlipressin and the initiation of vasodilator therapy, gangrene did not subside in our patient until his death on the 14th day.

This case suggests that despite its rarity, the possibility of ischaemic complications caused by terlipressin, must be borne in mind by clinicians. Recognising the risk factors, the immediate cessation of terlipressin and concomitant initiation of vasodilators can be helpful, albeit not always successful forms of treatment.

ACKNOWLEDGEMENTS

1. Source of funding: none.
2. Conflict of interest: none.

References:

1. Ozel Coskun BD, Karaman A, Gorkem H, Buğday I, Poyrazoğlu OK, Senel F: Terlipressin-induced ischemic skin necrosis: a rare association. *Am J Case Rep* 2014; 15: 476–479. doi: 10.12659/AJCR.891084.
2. Ortega R, Gines P, Uriz J *et al.*: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. *Hepatology* 2002; 36: 941–948.
3. Le Moine O, el Nawar A, Jagodzinski R *et al.*: Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. *Acta Gastroenterol Belg* 1998; 61: 268–270.

4. Heon JL, Myung JO: A case of peripheral gangrene and osteomyelitis secondary to terlipressin therapy in advanced liver disease. *Clin Mol Hepatol* 2013; 19: 179–184. doi: 10.3350/cmh.2013.19.2.179.
5. Megarbane H, Barete S, Khosrotehrani K et al.: Two observations raising questions about risk factors of cutaneous necrosis induced by terlipressin (Glypressin). *Dermatology* 2009; 218: 334–337. doi: 10.1159/000195676.
6. Halimi C, Bonnard P, Bernard B et al.: Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. *Eur J Gastroenterol Hepatol* 2002; 14: 153–158.
7. Kam PC, Williams S, Yoong FF: Vasopressin and terlipressin: pharmacology and its clinical relevance. *Anaesthesia* 2004; 59: 993–1001.
8. Sundriyal D, Kumar N, Patnaik I, Kamble V: Terlipressin induced ischaemia of skin. *BMJ Case Rep* 2013. doi: 10.1136/bcr-2013-010050.
9. Brodzky V, Farkas K, Jarai Z et al.: Efficacy of prostanoids in patients with critical leg ischemia. *Orv Hetil* 2011; 152: 2047–2055. doi: 10.1556/OH.2011.29277.
10. Banuelos Ramirez DD, Sanchez Alonso S, Ramirez Palma MM: Sildenafil in severe peripheral ischemia induced by terlipressin. A case report. *Reumatol Clin* 2011; 7: 59–60. doi: 10.1016/j.reuma.2010.05.005.
11. Yefet E, Gershovich M, Farber E, Soboh S: Extensive epidermal necrosis due to terlipressin. *Isr Med Assoc J* 2011; 13: 180–181.

Corresponding author:

Ankur Khandelwal

Department of Anaesthesiology

Sanjay Gandhi Post Graduate Institute Of Medical Sciences

(Sgpgims), Lucknow, Uttar Pradesh, India

e-mail: ankurchintus@gmail.com